Cagrilintide and CagriSema trial reference

Separate the names

Cagrilintide, also called AM833, is an investigational amylin analogue. CagriSema combines cagrilintide with semaglutide. CagriSema is not an alias for cagrilintide alone. Neither has an FDA approval as of November 6, 2026. Novo's November 4 report still makes a US CagriSema launch conditional on regulatory approval.

Read the treatment arms

The phase 2 cagrilintide trial studied adults without diabetes who had obesity, or overweight with hypertension or dyslipidemia. It compared once-weekly subcutaneous cagrilintide with placebo and once-daily liraglutide over 26 weeks. Cagrilintide groups lost more weight than placebo. Gastrointestinal events and injection-site reactions occurred.

REDEFINE 1 separately assigned adults without diabetes to CagriSema, either component alone, or placebo, alongside lifestyle intervention for 68 weeks. Novo's post hoc monotherapy analysis reported weight reduction of 11.5% with cagrilintide alone versus 3.0% with placebo under the treatment-policy analysis. That analysis includes outcomes regardless of adherence. The combination arm answers a separate question.

Cadence is a research fact

Once-weekly subcutaneous administration describes the studied cagrilintide route and cadence. It is not an approved prescribing schedule. A combination result does not establish the same effect for cagrilintide alone, and a commercial blend is not the studied combination product.

Record without inventing a regimen

For a clinician discussion, record the exact molecule or combination, intended purpose, other medicines, and the identity and source of any product already used. If enrolled in research, keep the trial identifier, formulation if disclosed, administration dates, symptoms, study-team contact, and written study instructions. Preserve blinding. The study team handles changes. Published treatment arms do not supply mixing instructions, a personal dose, or a recommendation to combine medicines.